Reims

• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended recruitment
  2023-505061-82-01 5 2024-06-17 Alopecia Areata
• Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Ended recruitment
  2023-508235-31-00 5 2024-06-17 Atopic Dermatitis
• Selective Treatment of Oral Povorcitinib in Vitiligo Study 1 (STOP-V1) Ended recruitment
  2023-505782-86-00 5 2024-04-23 Vitiligo
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit … Ended recruitment
  2023-505928-59-00 5 2024-04-15 Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
• TocilizuMab discontinuAtion in GIant Cell Arteritis Ended recruitment
  2023-505515-21-00 5 2024-04-02 Giant Cell Arteritis
• Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease Ended recruitment
  2023-504471-25-00 5 2024-03-01 Fibrotic Lung Disease
• PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed … Ended recruitment
  2023-505972-32-00 5 2024-02-26 locally advanced anal squamous cell carcinoma
• A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD … Ended recruitment
  2022-501343-33-00 5 2023-10-18 Biochemically recurrent prostate cancer
• Durvalumab (immunotherapy) maintenance after thoracic chemoradiotherapy (CRT) in frail small cell lung cancer patients whose disease is limi … Ended recruitment
  2024-512224-11-00 4 2023-03-24 Histologically confirmed frail Limited Disease Small Cell Lung Cancer
• Phase 1b study investigating the association of NP137 with Atezolizumab-Bevacizumab combination in first line in unresectable hepatocellular … Ended recruitment
  2022-500903-38-00 3 2023-02-09 unresectable hepatocellular carcinoma
• An extension study of long-term efficacy, safety and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed pr … Ended recruitment
  2024-510818-33-00 5 2023-01-24 Chronic Spontaneous Urticaria
• RITUX-PLUS 2 : A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of rituximab combined with subcutane … Ended recruitment
  2024-516168-27-00 5 2022-11-10 Adult patients with persistent or chronic immune thrombocytopenia
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended recruitment
  2024-515637-14-00 5 2022-11-08 Cystic Fibrosis
• Multicentric randomized phase I / II study to evaluate efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α True Human … Ended recruitment
  2024-517024-20-00 9 2022-09-27 Metastatic colorectal cancer patients
• Taletrectinib in ROS1 Positive Lung Cancer Phase 2 Global Study Ended recruitment
  2024-516604-41-00 4 2022-08-08 Non-small Cell Lung Cancer
• Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc … Ended recruitment
  2023-510097-14-00 5 2022-04-15 Patients with MMR deficient relapse or advanced / metastatic endometri
• Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial of therapeutic escalation, the POMEROL tri … Ended recruitment
  2023-508242-18-00 6 2021-12-21 Crohn's disease
• Multi-drug treatment for breast cancer patients with brain metastases Ended recruitment
  2024-510703-11-00 4 2021-12-13 HER2+ metastatic breast cancer with isolated brain progression
• Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC Ended recruitment
  2024-510809-28-00 5 2021-09-27 Metastatic Castration-sensitive Prostate Cancer
• Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended recruitment
  2024-510620-39-00 5 2021-04-19 Advanced RCC with clear cell component
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa … Ended recruitment
  2023-506911-16-00 5 2020-12-04 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment
  2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
• An open study for participants who have been on darolutamide treatment in any other Bayer study Ended recruitment
  2022-502084-38-00 5 2020-10-16 Cancer
• Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, … Ended recruitment
  2024-513005-31-00 5 2020-06-11 Patients with untreated metastatic Estrogen Receptor positive (ER+), H

Showing 145–168 of 208 trials